Hawkeye Bio’s graphene-biosensor lung cancer blood test LEAP becomes commercially available

Hawkeye Bio and HealthQuest Esoterics, a clinical reference laboratory in Irvine, California, have announced the commercial availability of LEAP (Lung Enzyme Activity Profile), a prescription blood test designed to support early lung cancer detection and complement low-dose CT screening.

LEAP uses Hawkeye’s graphene biosensor technology to measure patterns of protease enzyme activity associated with lung cancer. Testing is performed at HealthQuest’s CLIA-certified laboratory, with results available within seven days of sample receipt. The collaboration pairs Hawkeye’s biosensor and assay-development capabilities with HealthQuest’s laboratory validation, specimen-collection network and clinical testing operations, and the companies say it is a foundation for bringing additional diagnostic applications into clinical use as they are developed and validated.

Read More Graphene-Info – Graphene industry portal